Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
19 Dezembro 2024 - 2:00PM
UK Regulatory
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
Jean-Paul Kress to join Sanofi's Board of
Directors
Paris, December 19, 2024.
Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress
as an independent director as of January 1, 2025, replacing Gilles
Schnepp who has decided to leave the Board at the end of 2024.
Jean-Paul Kress will hold his position for the remainder of Gilles
Schnepp's term of office and his appointment will be subject to
ratification at the next Ordinary Shareholders' Meeting of
Sanofi.
Jean-Paul Kress, M.D., served
as the CEO of MorphoSys from 2019 until it was acquired by Novartis
in 2024. He led the company in its mission – More life for
people with cancer – and has spearheaded its transformation
into a global biopharmaceutical company developing and
commercializing novel cancer medicines. Prior to this, Jean-Paul
Kress was the CEO of Syntimmune, where he sharpened the company’s
focus on late-stage clinical development in auto-immune diseases
until the company’s acquisition by Alexion. He has also held
several senior leadership roles at other pharmaceutical companies
in the US and in Europe. Jean-Paul Kress served as Chairman of the
Board of Directors at ERYTECH Pharma and was a member of Sarepta
Therapeutics’ Board of Directors. He received his M.D. from Faculté
Necker-Enfants Malades in Paris and Master of Sciences in molecular
and cellular pharmacology from Ecole normale supérieure (Ulm) in
Paris.
Frédéric Oudéa
Chairman of the Board of Directors
"I extend my heartfelt gratitude to Gilles Schnepp for his
unwavering dedication to the Board, and particularly his pivotal
contribution to the evolution of the company’s governance in 2023.
The Board is delighted to welcome Jean-Paul Kress as its newest
director. With over 30 years of diverse executive experience in the
pharmaceutical sector, spanning large corporations and biotech
firms, Jean-Paul brings exceptional global expertise to the Board.
His insights will be invaluable in guiding the company’s ongoing
strategic evolution in the biopharmaceutical field."
Regarding the organization of the Board
Committees, Patrick Kron will take over as Chairman of the
Appointments, Governance and CSR Committee and Jean-Paul Kress will
join the Strategy Committee and the Scientific Committee.
About Sanofi
We are an innovative global healthcare company, driven by one
purpose: we chase the miracles of science to improve people’s
lives. Our team, across the world, is dedicated to transforming the
practice of medicine by working to turn the impossible into the
possible. We provide potentially life-changing treatment options
and life-saving vaccine protection to millions of people globally,
while putting sustainability and social responsibility at the
center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 |
sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 |
evan.berland@sanofi.com
Nicolas Obrist | + 33 6 77 21 27 55 |
nicolas.obrist@sanofi.com
Léo Le Bourhis | + 33 6 75 06 43 81 |
leo.lebourhis@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 |
victor.rouault@sanofi.com
Timothy Gilbert | + 1 516 521 2929 |
timothy.gilbert@sanofi.com
Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 |
thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 |
alize.kaisserian@sanofi.com
Felix Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.com
Keita Browne | + 1 781 249 1766 |
keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Tarik Elgoutni | + 1 617 710 3587 |
tarik.elgoutni@sanofi.com
Thibaud Châtelet | + 33 6 80 80 89 90 |
thibaud.chatelet@sanofi.com
- 2024_12_19_GPR_Board appointment_ENG
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
